

# MEDICAL POLICY UPDATE

## IN THIS ISSUE

**POLICY** .....

Update: Policy Criteria Established ..... 8

Update: Policy Guidelines Archived..... 11

Criteria for TheraSkin Is Being Revised ..... 11



## Policy

Policy Titles	Anticipated Issue Date	30 Day Notification Information
A-0167 - CG Cardiac Pacemaker Implantation or Replacement	09/30/2024	This MCG guideline was fully adopted in May of 2023. It will now be customized to add procedure codes 33262, 33263, 33264, and 33273. These codes will be added to the prior authorization list. This guideline will publish on September 30, 2024.
A-0433 - Pregnant Uterus, Transabdominal Ultrasound	10/07/2024	This is a new MCG fully adopted guideline, Pregnant Uterus, Transabdominal Ultrasound. The guideline will publish on October 7, 2024.
A-0434 - Pregnant Uterus, Transvaginal Ultrasound	10/07/2024	This is a new fully adopted MCG Guideline, Pregnant Uterus, Transvaginal Ultrasound. The guideline will publish on October 7, 2024.
A-0532 - Breast Cancer Gene Expression Assays	12/02/2024	This is a new policy for NY only. This policy will publish on December 2, 2024.
A-0581 - Neurofibromatosis - NF1 Gene	12/02/2024	This MCG guideline is being presented for full adoption for NY only. It is recommended to adopt this guideline and it will be scheduled to be activated on December 2, 2024.
A-0582 - (Hereditary) - Gene Panel Multiple Endocrine Neoplasia (MEN) Syndrome, Type 1 - MEN1 Gene	12/02/2024	This MCG guideline is being presented for full adoption for NY only. It is recommended to adopt this guideline and it will be scheduled to be activated on December 2, 2024.
A-0611 - Niemann-Pick Disease (Acid Sphingomyelinase Deficiency) - NPC1, NPC2, and SMPD1 Genes	12/02/2024	This MCG guideline is being presented for full adoption for NY only. It is recommended to adopt this guideline and it will be scheduled to be activated on December 2, 2024.

A-1 - Anesthesia Provided in Conjunction with Non-cover	09/30/2024	This is an annual review. There are no recommended changes to criteria. This policy will publish on September 30, 2024.
E-1 - Durable Medical Equipment (DME)	09/30/2024	This is an annual review. There are no recommended changes to coverage criteria. Diagnosis codes were updated. This policy will publish on September 30, 2024.
MA E-1 - Durable Medical Equipment Reference List	09/30/2024	This is an annual review. The policy was updated to capture CMS compliance updates. The policy will publish on September 30, 2024.
E-12 - Beds - Accessories and Related Items	09/30/2024	This is an annual review. There are no recommended changes to coverage criteria. This policy will publish on September 30, 2024.
G-46 - Inhaled Nitric Oxide	10/07/2024	This policy is scheduled for annual review. The policy will be archived. The policy will publish on October 7, 2024.
I-24 - Belatacept (Nulojix)	10/14/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. The policy will publish on October 14, 2024.
I-25 - Desensitization Treatment for Heart and Renal Transplant	09/30/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Minor administrative changes were made to the policy. The policy will publish on September 30, 2024.
I-27 - Certolizumab (Cimzia®)	11/25/2024	This policy is up for annual review. The policy was updated to include which type of specialist should be prescribing the medication based on indication. Policy will publish on November 25, 2024.
I-28 - Infliximab and Infliximab Biosimilars	11/25/2024	This policy is up for annual review. Criteria was revised to require a specialist to prescribe so that the policy is aligned with Pharmacy. The policy will publish on November 25, 2024.
I-31 - Tocilizumab (Actemra®)	11/25/2024	This policy is up for annual review. The policy was updated to include which type of specialist should be prescribing the medication based on indication, in order to align with pharmacy policy criteria. Criteria was also established for the FDA expanded indication for Tofidence for treatment of Giant Cell Arthritis (GCA). Policy will publish on November 25, 2024.
I-35 - Golimumab (Simponi®, Simponi Aria®)	11/25/2024	This policy is up for annual review. The policy was updated to include which type of specialist should be prescribing the medication based on indication, in order to align with pharmacy policy criteria. Additional administrative changes were also made to the policy. Policy will publish on November 25, 2024.

I-37 - Ustekinumab (Stelara®)	11/25/2024	This policy is up for annual review. The policy was updated to capture new NCCN recommendations for immune-checkpoint inhibitor-related toxicity. Policy was also updated to add which type of specialist should be prescribing the medication based on indication, in order to align with pharmacy policy criteria. Policy will publish on November 25, 2024.
I-38 - Rituximab (Rituxan®)	11/25/2024	This policy is up for annual review. The RA reauthorization criteria requiring the trial and failure of preferred products has been removed. The criteria for RA was also revised to require a specialist to prescribe. Coding was updated to NCCN recommendations. The policy will publish on November 25, 2024.
MA I-38 - Rituximab (Rituxan)	11/25/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Coding is being updated per NCCN recommendations. Policy will publish on November 25, 2024.
I-90 - Abatacept (Orencia®) IV and SC	11/25/2024	This policy is up for annual review. The policy was updated to capture the new FDA expanded indication for psoriatic arthritis to lower the minimum age to 2 years of age or older for the SC product. Policy was also updated to capture new NCCN recommendations for immune checkpoint related toxicities. The policy was updated to include which type of specialist should be prescribing the medication based on indication, in order to align with pharmacy policy criteria. Policy will publish on November 25, 2024.
MA I-90 - Abatacept (Orencia) IV	11/25/2024	This policy is up for annual review. Coding was updated to match NCCN recommendations. Policy will publish on November 25, 2024.
I-129 - Vedolizumab (Entyvio)	11/25/2024	This policy is up for annual review. The policy criteria was revised to add the requirement for a specialist prescriber. Criteria was also established for GHVD and Immune Checkpoint Inhibitor Toxicity. Coding was also updated. Policy will publish on November 25, 2024.
MA I-129 - Vedolizumab (Entyvio®)	11/25/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Coding was updated to match NCCN recommendations. Policy will publish on November 25, 2024.
I-130 - Complement Inhibitors (Soliris, Ultomiris, Empaveli)	09/02/2024	This policy is being updated with new to market therapy Piasky. Policy will publish September 2, 2024.

MA I-130 - Complement Inhibitors (Soliris, Ultomiris, Empaveli)	09/02/2024	This policy is being updated with new to market therapy Piasky. Policy will publish September 2, 2024.
MA I-139 - Ustekinumab (Stelara®)	11/25/2024	This policy is up for annual review. There are no indications for a change in coverage at this time, administrative changes were added to reflect coding that was in place. Policy will publish on November 25, 2024.
I-151 - Site of Care	09/01/2024	The policy is being revised to add Kisunla to the site of care program effective September 1, 2024.
I-170 - Siltuximab (Sylvant)	09/30/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Policy will publish on September 30, 2024.
MA I-170 - Sylvant	09/30/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Policy will publish on September 30, 2024.
MA I-184 - Certolizumab (Cimzia)	11/25/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Policy will publish on November 25, 2024.
MA I-194 - Tocilizumab (Actemra)	11/25/2024	This policy is up for annual review. Eligible diagnosis codes were added for the new FDA expanded indication for Tofidence for treatment of Giant Cell Arteritis (GCA). Policy will publish on November 25, 2024.
MA I-199 - Interleukin-23 Antagonists	09/02/2024	This policy is up for annual review. Policy and coding were updated to include criteria for mirikizumab-mrkz (Omvoh). Policy will publish on September 2, 2024.
I-199 - Interleukin-23 Antagonists (Ilumya SC and Skyrizi IV)	09/02/2024	This policy is being updated to establish criteria for mirikizumab-mrkz (Omvoh) for treatment of adults with moderate to severe ulcerative colitis. This policy will publish on September 2, 2024.
I-210 - IL-1 and IL-1b Blockers	10/14/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. The policy will publish on October 14, 2024.
WV MA I-210 - IL-1 and IL-1b Blockers	10/14/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. The policy will publish on October 14, 2024.

MA I-218 - Golimumab (Simponi, Simponi Aria)	11/25/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Policy will publish on November 25, 2024.
I-224 - Delaware Step Therapy Override Exception	10/14/2024	This policy is up for annual review. There are no updates to the mandate language and no change in coverage at this time. Policy will publish on October 14, 2024.
I-247 - Efgartigmod alfa-fcab (Vyvgart) and Efgartigmod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)	09/02/2024	This policy is up for annual review. Policy criteria was updated to exclude concurrent use with Zilbrysq. Criteria was established for Vyvgart Hytrulo's expanded indication of chronic inflammatory demyelinating polyneuropathy. Policy will publish on September 2, 2024.
I-252 - West Virginia Telemedicine Exception	10/14/2024	This policy is up for annual review. The mandate language remains the same and there are no indications for a change in coverage at this time. Policy will publish on October 14, 2024.
I-255 - Tenecteplase (TNKase)	10/14/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. The policy will publish on October 14, 2024.
MA I-256 - Efgartigmod alfa-fcab (Vyvgart) and Efgartigmod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)	09/02/2024	This policy is up for annual review. This policy is being revised to capture the diagnosis codes for the new FDA expanded indication for Vyvgart Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Policy will publish on September 2, 2024.
I-272 - Rozanolixizumab-noli (Rystiggo)	10/07/2024	This policy is up for annual review. The policy criteria was updated to exclude concurrent use with Zilbrysq. Policy will publish on October 7, 2024.
I-278 - Pozelimab-bbfg (Veopoz)	10/14/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. The policy will publish on October 14, 2024.
WV MA I-278 - Pozelimab-bbfg (Veopoz)	10/14/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. The policy will publish on October 14, 2024.
MA I-282 - Rozanolixizumab-noli (Rystiggo)	10/07/2024	This policy is up for annual review. There are no indications for a change in coverage at this time. Policy will publish on October 7, 2024.

I-291 - Donanemab (Kisunla)	09/02/2024	This is a new policy for the recently FDA approved medication donanemab (Kisunla). Donanemab will be considered experimental/investigational for commercial coverage. Policy will publish on September 2, 2024.
DE I-291 - Donanemab (Kisunla)	09/02/2024	This is a new policy for the state of Delaware for the recently FDA approved medication Donanemab (Kisunla) which is indicated for early Alzheimer's disease. Policy will publish on September 2, 2024.
L-115 - Testing for Fetal Chromosomal Microdeletions	12/02/2024	This is a new policy for NY only. This policy will have experimental/investigational criteria. Policy will publish on December 2, 2024.
L-123 - Liquid Biopsy Testing – Solid Tumors	12/02/2024	This is a new policy for NY only. This policy will publish on December 2, 2024.
L-216 - DecisionDX-UM	12/02/2024	This is a new medical policy for NY only. This policy will publish on December 2, 2024.
L-221 - Genetic Testing for Diseases of the Thyroid	12/02/2024	This is a new policy for NY only. This policy will have medically necessary criteria. This policy will publish on December 2, 2024.
L-222 - Multimarker Serum Testing Related to Ovarian Cancer	12/02/2024	This is a new policy for NY only. Criteria has been established for Multimarker Serum Testing Related to Ovarian Cancer. The policy will publish on December 2, 2024.
L-233 - Liver Fibrosis Laboratory Tests	12/02/2024	This is a new medical policy for NY only. This policy will publish on December 2, 2024.
L-271 - Testing for Hematologic Malignancies	12/02/2024	This is a new policy for NY only. This policy has medically necessary criteria. Policy will publish on December 2, 2024.
L-287 - Chromosomal microarray (CMA) /Array Comparative Genomic Hybridization (aCGH)	12/02/2024	This is a new medical policy for NY only. This policy will publish on December 2, 2024.
L-288 - Pediatric Panel Testing Guidelines	12/02/2024	This is a new medical policy for NY only. This policy will publish on December 2, 2024.
L-290 - Next-Generation Sequencing for the Assessment of Measurable Residual Disease Testing for Cancer	12/02/2024	This is a new medical policy for NY only. This policy will publish on December 2, 2024.
L-294 - Genetic Testing for Bladder Cancer	12/02/2024	This is a new policy for NY only. Policy will publish on December 2, 2024.
L-296 - Genetic Testing for Epilepsy	12/02/2024	This is a new policy for NY. This policy will publish on December 2, 2024.

MA N-24 - Miscellaneous Services	09/30/2024	This is an annual review. Procedure codes were added to and removed from the policy. The policy will publish on September 30, 2024.
NY MA N-24 - Miscellaneous Services	09/30/2024	This is an annual review. Procedure codes were added to and removed from the policy. The policy will publish on September 30, 2024.
O-10 - Dynamic Splinting Devices	10/07/2024	This is an annual review. The policy position was reorganized. The policy will publish on October 7, 2024.
S-33 - Bio-Engineered Skin and Soft Tissue Substitutes	11/11/2024	This policy is scheduled for annual review. Criteria was updated regarding the product TheraSkin. Addition of experimental/investigational CPT codes. The policy will publish on November 11, 2024.
S-46 - Mohs Micrographic Surgery (MMS)	10/07/2024	This policy is scheduled for annual review. There are no changes to criteria or coding. The policy will publish on October 7, 2024.
S-129 - Mastectomy and Reconstructive Surgery	10/07/2024	This policy is being updated to clarify and simplify indications for surgery on contralateral breast to produce symmetry. No operational guidelines were modified and this policy will publish on October 7, 2024.
S-180 - Recombinant and Autologous Platelet-Derived Gro	09/30/2024	This is an annual review. There are no recommended changes to coverage criteria. Coding has been updated. This policy will publish on September 30, 2024.
S-184 - Gender Reassignment Surgery	09/30/2024	This policy is scheduled for annual review. The language regarding mental health and hormone therapy was updated. The policy will publish on September 30, 2024.
S-237 - Discography	09/30/2024	This policy is scheduled for annual review. There are no indications for a change in coverage at this time. The policy will publish on September 30, 2024.
S-249 - Amniotic Membrane and Amniotic Fluid	09/30/2024	This policy is scheduled for annual review. Three Dx codes were added to the policy. There are no changes to criteria. The policy will publish on September 30, 2024.
X-21 - Mammography	10/07/2024	This policy is scheduled for annual review. There are no changes in coverage. The policy will publish on October 7, 2024.
Z-105 - Prescription Digital Therapeutics	09/30/2024	Minor language revision made to one of the digital therapeutics name. Coding updated. This policy will publish on September 30, 2024.



## Update: Policy Criteria Established



Highmark New York has established new policies, new guidelines, revised criteria for the following list of policies.

The effective date is December 2, 2024.

New Policies or Guidelines:

Policy or Guideline Number	Policy or Guideline Name
<b>A-0270-001 NY CG</b>	Brachytherapy
<b>A-0423-001 NY CG</b>	Stereotactic Radiosurgery
<b>A-0455-001 NY CG</b>	Intensity Modulated Radiation Therapy
<b>A-0499-001 NYCG</b>	Breast or Ovarian Cancer, Hereditary BRCA1 and BRCA2 Genes
<b>A-0532-001-NY CG</b>	Breast Cancer Gene Expression Assays
<b>A-0534</b>	Familial Adenomatous Polyposis-APC Gene
<b>A-0581</b>	Neurofibromatosis - NF1 Gene
<b>A-0582</b>	(Hereditary) - Gene Panel Multiple Endocrine Neoplasia (MEN) Syndrome, Type 1 - MEN1 Gene
<b>A-0583</b>	Von Hippel-Lindau Syndrome - VHL Gene
<b>A-0585</b>	Cowden Syndrome - PTEN Gene
<b>A-0586</b>	Retinoblastoma - RB1 Gene
<b>A-0590</b>	Alzheimer Disease (Early Onset) - APP, PSEN1, and PSEN2 Genes
<b>A-0591</b>	Amyotrophic Lateral Sclerosis (ALS) - C9orf72, FUS, SOD1, and TARDBP Genes
<b>A-0592</b>	Ashkenazi Jewish Genetic Carrier Panel
<b>A-0594</b>	Brugada Syndrome Channelopathy Genes
<b>A-0597</b>	Cystic Fibrosis-CFTR Gene and Mutation Panel
<b>A-0600</b>	Factor V Leiden Thrombophilia - F5 Gene
<b>A-0602</b>	Fragile X Syndrome-FMR1 Gene
<b>A-0608</b>	Muscular Dystrophies (Duchenne/Becker)-DMD Gene
<b>A-0611</b>	Niemann-Pick Disease (Acid Sphingomyelinase Deficiency) - NPC1, NPC2, and SMPD1 Genes
<b>A-0612</b>	Prostate Cancer - BRCA1 and BRCA2 Genes
<b>A-0613</b>	Prothrombin Thrombophilia - F2 Gene
<b>A-0614</b>	Tay-Sachs Disease Testing
<b>A-0615</b>	Wilms Tumor - WT1 Gene
<b>A-0627</b>	Arrhythmogenic right Ventricular Cardiomyopathy
<b>A-0633</b>	Familial Hypertrophic Cardiomyopathy, Nonsyndromic- Gene and Gene Panel Testing
<b>A-0646</b>	Pancreatitis, Hereditary - CFTR, CPA1, CTSC, PRSS1, and SPINK1 Genes
<b>A-0648</b>	Familial Dilated Cardiomyopathy-Gene and Gene Panel Testing



<b>A-0659</b>	Spinal Muscular Atrophy - SMN1 and SMN2 Genes
<b>A-0691</b>	Charcot-Marie-Tooth Hereditary Neuropathy - Gene and Gene Panel Testing
<b>A-0694-001 NY CG</b>	Stereotactic Body Radiotherapy
<b>A-0704</b>	Hereditary Hemorrhagic Telangiectasia - ACVRL1, ENG, GDF2, and SMAD4 Genes
<b>A-0707</b>	Prader-Willi Syndrome DNA Methylation Testing
<b>A-0708</b>	Angelman Syndrome - UBE3A Gene
<b>A-0724</b>	Noninvasive Prenatal Testing (Cell-Free Fetal DNA - Aneuploidy Testing
<b>A-0762</b>	Axial Spondyloarthritis - HLA-B27 Testing
<b>A-0767</b>	Breast Cancer (Hereditary) - Gene Panel
<b>A-0769</b>	Celiac Disease - HLA Testing
<b>A-0773</b>	Colorectal Cancer - Gene Testing (Somatic or Therapeutic)
<b>A-0774</b>	Colorectal Cancer (Hereditary) - Gene Panel
<b>A-0778</b>	Familial Thoracic Aortic Aneurysm and Aortic Dissection - Gene Testing and Gene Panels
<b>A-0780</b>	Gastrointestinal Stromal Tumor (GIST) - KIT and PDGFRA Genes
<b>A-0782</b>	Ovarian Cancer (Hereditary) - Gene and Gene Panel Testing
<b>A-0788</b>	Marfan Syndrome-FBN1 Gene
<b>A-0797</b>	Pancreatic Cancer (Hereditary)-Gene Panel
<b>A-0798</b>	Paraganglioma-Pheochromocytoma (Hereditary) - Gene Testing and Gene Panel
<b>A-0808</b>	Alpha Thalassemia - HBA1 and HBA2 Genes
<b>A-0815</b>	Beta Thalassemia - HBB Gene
<b>A-0823</b>	Deafness and Hearing Loss, Nonsyndromic- Gene and Gene Panel Testing
<b>A-0828</b>	MUTYH-Associated Polyposis - MUTYH Gene
<b>A-0842</b>	Multiple Endocrine Neoplasia (MEN) Syndrome, Type 2 - RET Gene
<b>A-0846</b>	Neurofibromatosis - NF2 Gene
<b>A-0849</b>	Noninvasive Prenatal Testing (Cell-Free Fetal DNA) - Monogenic Disorders
<b>A-0850</b>	Noninvasive Prenatal Testing (Cell-Free Fetal DNA) - Sex Chromosome Disorders
<b>A-0864</b>	Sickle Cell Disease - HBB Gene
<b>A-0907</b>	Friedreich Ataxia-FXN Gene
<b>A-0908</b>	Spinocerebellar Ataxia - Gene Testing and Gene Panels
<b>A-0909</b>	Loeys- Dietz Syndrome - Gene and Gene Panel Testing
<b>A-0910</b>	Ehlers-Danlos Syndrome (Vascular) - COL3A1 Gene
<b>A-0912</b>	Retinal Disorders (Hereditary) - Gene Panels
<b>A-0915</b>	Noonan Syndrome - Gene and Gene Panel Testing
<b>A-0918</b>	Long QT Syndrome (Hereditary) - Gene and Gene Panel Testing
<b>A-0958</b>	Familial Hypercholesterolemia- APOB, LDLR, and PCSK9 Genes)
<b>A-1005</b>	Narcolepsy-HLA Testing
<b>A-1006</b>	Alpha-1 Antitrypsin Deficiency - SERPINA1 Gene
<b>L-115</b>	Testing for Fetal Chromosomal Microdeletions
<b>L-123</b>	Liquid Biopsy Testing – Solid Tumors
<b>L-124</b>	Somatic Biomarker Testing for Solid Tumors
<b>L-191</b>	Intracellular Micronutrient Testing Panel
<b>L-195</b>	Genetic Testing: Germline Cancer Testing after Somatic Testing

L-216	Uveal Melanoma: DecisionDx
L-221	Genetic Testing for Diseases of the Thyroid
L-222	Multimarker Serum Testing Related to Ovarian Cancer
L-229	Genetic Testing for Mitochondrial Disorders
L-233	Liver Fibrosis Laboratory Tests
L-235	Genetic Testing: Polymerase Gamma (POLG) Related Disorders
L-261	Experimental/Investigational Laboratory Services
L-271	Testing for Hematologic Malignancies
L-274	Red Blood Cell (RBC) Antigen Genotyping
L-275	Fetal RhD Genotyping Using Maternal Plasma
L-276	Genetic Testing for Alzheimer Disease
L-277	Laboratory Administrative Guidelines
L-280	Pharmacogenetic/Pharmacogenomic Testing
L-284	Laboratory Testing: Medical Necessity
L-285	General Approach to Genetic Testing
L-286	Chromosome Analysis (Karyotype)
L-287	Chromosomal microarray (CMA) /Array Comparative Genomic Hybridization (aCGH)
L-288	Pediatric Panel Testing Guidelines
L-289	Expanded Carrier Screening Guidelines
L-290	Next-Generation Sequencing for the Assessment of Measurable Residual Disease Testing for Cancer
L-292	Genetic Testing for Autism
L-293	Genetic Testing for Benign Hematology
L-294	Genetic Testing for Bladder Cancer
L-295	Genetic Testing for Idiopathic Pulmonary Fibrosis
L-296	Genetic Testing for Epilepsy
L-297	Genetic Testing for Pain
L-299	Genetic Testing for Intellectual Disability
L-300	Genetic Risk Stratification for Skin Cancer
L-301	Molecular Testing in the Management of Pulmonary Nodules
L-302	Genetic Testing for Prostate Cancer
L-303	Renalix- KidneyIntelX
L-304	Whole Genome Sequencing/Whole Exome Sequencing
L-96	Biomarkers in Risk Assessment and Management of Cardiovascular Disease
R-76-001 HMK NY	Hyperthermia

At that time, coverage guidelines can be accessed utilizing the live link from the medical policy website.

---

## Update: Policy Guidelines Archived



Highmark New York has communicated the following new guidelines in the February 2024 MPU; however, these will no longer be effective.

Archived guidelines effective immediately:

Policy or Guideline Number	Policy or Guideline Name
A-0856	Prostate Cancer Gene Expression Testing-Decipher
A-0905	Epilepsies (Hereditary) - Gene Panels
A-0861	Behavioral Health Medication Pharmacogenetics - Gene Panels
A-0923	Intellectual Disability - Gene Panels
A-0687	Rett Syndrome - CDKL5, FOXP1, and MECP2 Genes
A-0595	Canavan Disease Genetic Testing

---

## Criteria for TheraSkin Is Being Revised



The following criteria is being removed from Medical Policy S-33, Bioengineered Skin, for the utilization of the product TheraSkin.

“Other uses supported by clinical results and clinical literature include pressure sores, skin cancer excision (e. g., Mohs Surgery), large surgical wounds (e. g., club release, etc.), radiation compromised wounds and necrotizing fasciitis.”

These indications will no longer be covered.

This revised Medical Policy will apply to professional providers and facility claims). The effective date is November 11, 2024

### **Place of Service: Outpatient**

Please refer to Medical Policy S-33, Bioengineered Skin, for additional information.



## Comments on These Medical Policies?

We want to know what you think about our new medical policy changes. Send us an email with any questions or comments that you may have on the new medical policies in this edition of Medical Policy Update.

Write to us at [medicalpolicy@highmark.com](mailto:medicalpolicy@highmark.com)



## eSubscribe

[Highmark Blue Cross Blue Shield \(DE\)](#)

[Highmark Blue Cross Blue Shield \(NY\)](#)

[Highmark Blue Cross Blue Shield \(PA\)](#)

[Highmark Blue Cross Blue Shield \(WV\)](#)



## About this Newsletter

*Medical Policy Update* is a monthly newsletter for the health care providers who participate in our networks and submit claims to Highmark using the appropriate HIPAA transactions or claim forms as required by Highmark. This publication focuses only on medical policy and claims administration updates, including coding guidelines and procedure code revisions, and is the sole source for this information. For all other news, information, and updates, be sure to read *Provider News*, available on the Provider Resource Center.

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. All references to “Highmark” in this document are references to the Highmark company that is providing the member’s health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

*Note: This publication may contain certain administrative requirements, policies, procedures, or other similar requirements of Highmark Inc. (or changes thereto) as well as interpretations of certain administrative requirements, policies and procedures (hereinafter collectively “requirements”) which are binding upon Highmark Inc. and its contracted providers. Therefore, the requirements in this publication supplement the Provider Manual. Pursuant to their contract, Highmark Inc.*